Literature DB >> 19423467

Antimicrobial resistance in relation to virulence determinants and phylogenetic background among uropathogenic Escherichia coli in Lebanon.

G Sawma-Aouad1, F Hashwa, S Tokajian.   

Abstract

Escherichia coli is the most common causative agent of recurrent, uncomplicated urinary tract infections. Triplex pCR and the disc diffusion method were used to determine and correlate among the phylogenetic group, virulence determinants and antimicrobial resistance in 100 uropathogens. Group B2 represented 58% of the tested isolates with no isolates belonging to group B1. Isolates with the highest percentage of susceptibility to all antimicrobial agents used were within the B2 phylogenetic groups. 38% of the tested population were resistant to trimethoprim/sulfamethoxazole, 29% to ciprofloxacin and only 8% to nitrofurantoin. The majority of the isolates resistant to trimethoprim/sulfamethoxazole were from group B2 (52.7%), with 45% being positive to the three tested virulence determinants (efu, fbp and picU). These findings suggest that although virulence and antimicrobial resistance are mutually exclusive in Escherichia coli clinical isolates, the relationship between virulence and resistance to antimicrobial agents can vary according to the particular resistance phenotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19423467     DOI: 10.1179/joc.2009.21.2.153

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  2 in total

1.  Antibiotic resistance, phylogenetic typing, and virulence genes profile analysis of uropathogenic Escherichia coli isolated from patients in southern Iraq.

Authors:  Mohammed Allami; Masoumeh Bahreini; Mohammad Reza Sharifmoghadam
Journal:  J Appl Genet       Date:  2022-02-10       Impact factor: 3.240

2.  Antimicrobial resistance patterns and integron carriage of Escherichia coli isolates causing community-acquired infections in Turkey.

Authors:  Aysegul Copur-Cicek; Osman Birol Ozgumus; Aysegul Saral; Cemal Sandalli
Journal:  Ann Lab Med       Date:  2014-02-13       Impact factor: 3.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.